Venous Leg Ulcer (VLU)NCT07549737
Effectiveness of Silicone Superabsorbent Polymer Dressings for Chronic Wound Management
A study testing RespoSorb Silicone (RSSil) and RespoSorb Silicone Border (RSSB) in people with Venous Leg Ulcer (VLU) and Diabetic Foot Ulcer (DFU), run by HARTMANN GROUP at 8 sites in Poland.
Trial summary
The purpose of this single arm clinical study is to find out how well two Silicone superabsorbent polymer dressings, RespoSorb Silicone (also known as Zetuvit Plus Silicone) and RespoSorb Silicone Border (also known as Zetuvit Plus Silicone Border), work in treating long lasting wounds on the lower legs or feet. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Venous Leg Ulcer (VLU), Diabetic Foot Ulcer (DFU)
- What is being tested?
- RespoSorb Silicone (RSSil) and RespoSorb Silicone Border (RSSB)
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 80 participants
- Where
- 8 sitesPoland
- Study dates
- 17 Jul 2024to 23 Aug 2025
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Patient is 18 years of age or older and has given formal written consent.
- Diagnosed with a chronic, exuding lower extremity wound of a single limb:
- Venous leg ulcer (VLU) or
- Diabetic Foot Ulcer (DFU).
- Target ulcer persists since min. 1 and max. 12 months prior to screening.
- An appropriate dressing size is available to be used according to the size of the target ulcer, the ulcer size shall be no longer than 10 cm in one dimension.
Show all 13Show fewer
- Target ulcer is not clinically infected ( Clinically infected wound is defined as a wound that required the use of systemic antibiotics or topical antimicrobials ).
- Ankle-brachial pressure index (ABPI) is between 0.8 and 1.2 measured during the Screening or within 30 days prior to the Screening Visit. If ABPI is >1.2 the Toe-Brachial Index (TBI) should be >0.6.
- Presence of an ulcer extending through the full thickness of the skin but not down to muscle, tendon or bone.
- For VLU: Patient is suitable for and agrees to use compression therapy (PütterPro2 or PütterPro2 Lite) for the study duration and was using compression therapy before study inclusion.
- For VLU: Patient is able to walk in conjunction to compression therapy. Ankle mobility is fully mobile to limited mobile.
- For DFU: Patient is suitable and agrees to use offloading devises for the study duration.
- For DFU: Patient is able to walk in conjunction to offloading devices. Ankle mobility is fully mobile to limited mobile.
Who cannot join
- Known allergies/hypersensitivity or intolerance to any of the study product ingredients.
- Patients with ischemic diabetic foot ulcers.
- Patients with more than two full-thickness lower extremity ulcers on the same limb or greater than a total of three full-thickness lower-extremity ulcers.
- Target ulcer is clinically infected according to the judgement of HCP or suspected to be clinically infected that could require systemic antibiotics at the time of screening or during the study.
- Treatment with local or systemic antimicrobial therapy within 7 days prior to Screening visit or during the study duration.
- According to physician's assessment, the patient is not able to follow the study protocol (e.g. due to cognitive disease) or is not able to understand state, nature, meaning and consequences of the study.
Show all 28Show fewer
- Patient suffers from active autoimmune disease requiring corticosteroid treatment (> 10 mg prednisolone equivalent/day) and/or other immunosuppressive (e.g. cyclosporine (>10mg/kg), methotrexate (>10mg/week), TNF inhibitors (e.g. infliximab) and/ or chemotherapy within 7 days prior to Screening visit or during the study duration.
- Application of topical steroids to the ulcer surface 7 days prior to treatment or during the course of the study.
- Hyperbaric treatment 7 days prior to treatment or during the course of the study.
- Bioengineered tissue product usage on the target ulcer four weeks prior to treatment or during the course of the study.
- Patients with clinically significant intermittent claudication (the symptoms significantly impact a person's ability to walk and perform daily activities).
- Patients where the full dimensions of their leg ulcer could not be measured (it must be possible to display the entire wound area on one photo from a distance of 25-30 cm).
- Wound is caused by malign tumor (primary or metastasis). Any malignancy within the past three years, excluding successfully treated basal cell carcinoma or squamous cell carcinoma without evidence of metastases.
- History of radiation to the target ulcer site within 12 months prior to screening.
- Patients with known history of having Acquired Immunodeficiency Syndrome (AIDS) or with a history known to be infected with Human Immunodeficiency Virus (HIV).
- Recurrent ulcer (the target ulcer has re-occurred within 12 months after its complete closure).
- Patients with NYHA Class IV congestive heart failure (CHF).
- Patients with hypertensive leg ulcers (Ulcus cruris hypertonicum Martorell).
- Patient suffers from septic phlebitis, severe deep vein thrombosis (phlegmasia cerulea dolens) or other conditions posing a contraindication for compression therapy according to established guidelines and local procedures (e.g. significant sensory neuropathy).
- In addition to study product, further products in direct contact to wound surface will be used.
- Documented history of osteomyelitis at the target ulcer location within six months preceding the screening visit.
- Patients with oedema that cannot be controlled with compression therapy.
- Patient suffers from poorly controlled diabetes (Hb1Ac ≥ 8.6%) measured within 3 months before screening or at the time of screening visit.
- Patient suffered from significant malnutrition with reduced serum albumin levels - serum albumin concentration is below 3.5 g/dL measured within 2 weeks before screening or at the time of screening visit.
- Patients with a known history of alcohol use disorder and substance use disorder as defined by the Diagnostic and Statistical Manual of Mental Disorders, fifth edition (DSM-5) within the past year.
- Participation in any interventional study in the last 7 days before beginning of this study.
- Patients with severe obesity (BMI>40) that limited their mobility.
- Female patients of childbearing age not using contraception, pregnancy (suspected or confirmed), or breast-feeding women.
Trial locations and contacts
8 sites in 1 country.
8 sites in 1 country
Poland8 sites
JBS Klinika Spółka Z Ograniczoną Odpowiedzialnością
Gdansk
MelissaMed Poradnia Chirurgiczna
Lodz
MIKOMED Spółka Z Ograniczoną Odpowiedzialnością
Lodz
Niepubliczny Zakład Opieki Zdrowotnej "Argo" Centrum Medyczne
Lodz
Specjalistyczny Osrodek Leczniczo Badawczy, Zbigniew Żęgota
Ostróda
PODOVIA Sp. z o.o.
Poznan
Niepubliczny Specjalistyczny Zakład Opieki Zdrowotnej "Medicus", Poradnia Chirurgiczna
Środa Wielkopolska
Lecran - Centrum Opieki Nad Ranami-Kunickiego
Wroclaw
About this study
Official title: A Prospective, Single-arm, Cohort Post Market Clinical Follow Up Investigation to Follow Evolution of the Healing of Exuding Chronic Leg Ulcers Treated With RespoSorb Silicone Border and RespoSorb Silicone Dressings.
The purpose of this single arm clinical study is to find out how well two Silicone superabsorbent polymer dressings, RespoSorb Silicone (also known as Zetuvit Plus Silicone) and RespoSorb Silicone Border (also known as Zetuvit Plus Silicone Border), work in treating long lasting wounds on the lower legs or feet. The main goal of the study is to see whether these dressings help reduce wound size over time.
The study also looks at whether the dressings improve the condition of the wound and the surrounding skin. In addition, patients are asked about their experience with the dressings, including whether they help reduce pain and how satisfied patients are with the treatment.
Read the detailed description
This prospective, non comparative, single arm clinical investigation is conducted as part of Post Market Clinical Follow up (PMCF) activities to evaluate the clinical performance and safety of two Silicone SAP dressings: RespoSorb Silicone (RSSil; also marketed as Zetuvit Plus Silicone) and RespoSorb Silicone Border (RSSB; also marketed as Zetuvit Plus Silicone Border) in the management of chronic, exuding lower extremity wounds.
Approximately 80 evaluable adult patients with a single chronic VLU or DFU will be enrolled at 7 to 10 clinical sites in Poland, including outpatient clinics and hospitals. In each dressing group, at least 35% of patients will have VLU and at least 35% DFU. Patients with VLU will receive compression therapy, and patients with DFU will use appropriate offloading devices throughout the study.
Patients will be followed for up to 6 weeks or until wound healing, discontinuation, withdrawal, or occurrence of an adverse event preventing further participation. The primary objective is to evaluate the potential clinical effectiveness of RSSil and RSSB in reducing wound size over time. Wound area will be measured objectively by planimetry using standardized photographs taken at each visit.
Secondary outcomes include changes in wound tissue composition (granulation and slough), exudate amount and type, peri wound skin condition, frequency of dressing changes, and patient reported outcomes such as treatment benefit and wound related quality of life. Physical activity will be assessed using a wrist worn accelerometer, and compliance with compression therapy (VLU) or offloading devices (DFU) will be documented. In addition, healthcare professionals will provide feedback on usability and overall experience with the dressings.
Safety will be assessed by monitoring and recording device related adverse events and device deficiencies throughout the study. Data will be captured using an electronic case report form and analyzed primarily using an intention to treat approach.
- Conditions
- Venous Leg Ulcer (VLU), Diabetic Foot Ulcer (DFU)
- Being tested
- RespoSorb Silicone (RSSil), RespoSorb Silicone Border (RSSB)
- Keywords
- Venous leg ulcer, Diabetic Foot Ulcer, Silicone superabsorbent dressings
- Medical subject headings
- Varicose Ulcer, Diabetic Foot
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
RespoSorb Silicone (RSSil)Device
Also called Zetuvit Plus Silicone
RespoSorb Silicone is a Silicone Superabsorbent Polymer (SAP) dressing intended for the management of chronic, exuding lower extremity wounds. The dressing consists of a superabsorbent core designed to absorb and retain wound exudate and a soft silicone contact layer that allows gentle adhesion to the peri-wound skin while minimizing trauma and pain during dressing changes.
RespoSorb Silicone is applied directly to the wound bed and secured with an appropriate secondary fixation according to standard clinical practice and the manufacturer's Instructions for Use. Dressing changes are performed as clinically indicated. Treatment is continued for up to 6 weeks or until wound healing, discontinuation, or withdrawal.
RespoSorb Silicone Border (RSSB)Device
Also called Zetuvit Plus Silicone Border
RespoSorb Silicone Border is a Silicone Superabsorbent Polymer (SAP) dressing intended for the management of chronic, exuding lower extremity wounds. The dressing combines a superabsorbent core for effective exudate absorption and retention with a soft silicone contact layer to minimize disruption of the wound and peri-wound skin.
The dressing includes an integrated adhesive silicone border that provides secure fixation without the need for additional secondary dressings. RespoSorb Silicone Border is applied according to standard clinical practice and the manufacturer's Instructions for Use. Dressing changes are performed as clinically indicated. Treatment is continued for up to 6 weeks or until wound healing, discontinuation, or withdrawal.
| Study group | Role | What they receive |
|---|---|---|
| Silicone SAP Dressings (RespoSorb Silicone / RespoSorb Silicone Border) | Experimental | Single-arm cohort of adult patients with chronic, exuding lower extremity wounds treated with Silicone SAP dressings. Participants receive either RespoSorb Silicone or RespoSorb Silicone Border, selected based on wound characteristics and clinical judgement, and are followed prospectively to assess wound area reduction, wound-bed condition, patient-reported outcomes, and safety. Receives: Device: RespoSorb Silicone (RSSil); Device: RespoSorb Silicone Border (RSSB) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Wound area reduction
Clinical effectiveness will be assessed by the change in wound area of the target ulcer over time. Wound area will be calculated in square centimeters (cm²) using planimetric analysis based on standardized digital photographs taken at each study visit. The study has established a threshold for clinical significance, defining a minimum reduction in the wound area of 20%.
Measured: Up to 6 weeks (maximum total treatment period), or until wound healing, withdrawal, or discontinuation, whichever occurs first
Secondary outcomes (18)
Change in granulation tissue over time
Change in the proportion of the wound surface covered by granulation tissue will be assessed over time. Granulation tissue area (%) before and after cleansing/debridement will be evaluated based on standardized wound photographs obtained at each study visit. Changes in the coverage by granulation tissue at baseline and at the final visit determined as: None, 1%-24%, 25%-49%, 50%-74%, or 75%-100%.
Measured: Up to 6 weeks, or until wound healing, withdrawal, or discontinuation, whichever occurs first
Change in Slough Tissue Over Time
Change in the proportion of the wound surface covered by slough tissue will be assessed over time. Slough tissue area (%) before and after cleansing/debridement will be evaluated using standardized wound photographs taken at each study visit. Changes in the coverage by slough tissue at baseline and at the final visit determined as: None, 1%-24%, 25%-49%, 50%-74%, or 75%-100%.
Measured: Up to 6 weeks, or until wound healing, withdrawal, or discontinuation, whichever occurs first
Change in Exudate Amount Over Time
Exudate amount will be quantified as the fluid volume retained in each dressing. This will be calculated as the difference between wet and dry dressing weight, divided by the exudate fluid density (1.03 g/cm³). The exudate retention volume will be calculated as the daily exudate retention volume by dividing the fluid volume (V) by the wearing time (days) recorded in eCRF. Change in the daily exudate volume from baseline to the final visit in mL will be quantified.
Measured: Weekly assessments during the treatment period, up to 6 weeks, or until wound healing, withdrawal, or discontinuation, whichever occurs first.
Change in Exudate Type Over Time
Exudate type will be assessed qualitatively by the healthcare professional and classified as serous, sanguineous, serosanguineous, seropurulent, fibrinous, purulent, hemopurulent, or hemorrhagic. Changes in particular exudate types at baseline and the final visit will be assessed,
Measured: Up to 6 weeks, or until wound healing, withdrawal, or discontinuation, whichever occurs first
Improvement of Peri-Wound Skin Condition Over Time
Peri-wound skin condition will be evaluated visually by the investigator or designee for the presence or absence of maceration, erythema/redness, dry skin, and other peri-wound skin abnormalities. Changes in peri-wound skin condition from baseline to the final visit will be assessed.
Measured: Up to 6 weeks, or until wound healing, withdrawal, or discontinuation, whichever occurs first.
Patient-Reported Treatment Benefit (PBI-W)
Patient-reported treatment benefit will be assessed using the Patient Benefit Index for Wounds (PBI-W), which evaluates the patient's perceived benefit of treatment. Changes in the global PBI score at baseline and the final visit will be calculated. The global PBI-W score ranges from 0 (no patient-relevant treatment benefit) to 4 (maximum patient-relevant treatment benefit), with positive change indicating increased perceived benefit.
Measured: Assessed at baseline and at the end of treatment at 6 weeks or until healed or withdrawal/discontinuation, whichever occurs first.
Quality of Life of patients with chronic wounds
Wound-related quality of life will be assessed using the Wound-QoL-17 questionnaire, which measures disease-specific health-related quality of life over the preceding 7 days. Changes in the Wound-QoL 17 global score at baseline and final visit will be calculated. The global score ranges from 0 to 4, with higher scores indicating greater impairment in wound-related quality of life; therefore, a decrease in score represents an improvement in quality of life.
Measured: Assessed at baseline and at the end of treatment at 6 weeks or until healed or withdrawal/discontinuation, whichever occurs first.
Change in weekly Average Active Intensity
Activity intensity will be assessed using a wrist-worn accelerometer applied at baseline and worn throughout the study period. Active intensity per day is defined as the mean activity intensity of all periods classified as active (light, moderate, or vigorous activity) within a 24-hour period and expressed in metabolic equivalents (METs). Daily values will be aggregated to derive weekly average active intensity for each participant. Changes between week 1 and week 6 will be calculated.
Measured: Up to 6 weeks, or until wound healing, withdrawal, or discontinuation, whichever occurs first.
Change in Weekly Average Active Volume
Active volume will be assessed using a wrist-worn accelerometer applied at baseline and worn throughout the study period. Active volume per day represents the cumulative activity dose over a 24-hour period, calculated by integrating activity intensity across all recorded activity events and expressed as metabolic equivalent minutes per day (MET-minutes/day). Daily values will be aggregated to compute weekly average active volume per participant. Change in Active volume between week 1 and week 6 will be calculated.
Measured: Up to 6 weeks, or until wound healing, withdrawal, or discontinuation, whichever occurs first.
Change in Weekly Average Moderate-to-Vigorous Physical Activity (MVPA) Duration
MVPA duration will be assessed using a wrist-worn accelerometer applied at baseline and worn throughout the study period. MVPA duration is defined as the total daily time spent in activity exceeding predefined intensity thresholds corresponding to moderate or vigorous activity and reported in hours. Daily values will be aggregated to compute weekly average MVPA duration per participant. Change in MVPA duration between week 1 and week 6 will be calculated.
Measured: Up to 6 weeks, or until wound healing, withdrawal, or discontinuation, whichever occurs first.
Change in Weekly Average Active-to-Inactive Duration Ratio
The active-to-inactive duration ratio will be assessed using a wrist-worn accelerometer applied at baseline and worn throughout the study period. Active duration includes all periods classified as light, moderate, or vigorous activity. Inactive duration includes all inactive time excluding sleep. Daily values will be aggregated to compute weekly average active-to-inactive duration ratios per participant. Change in active-to-inactive duration ratio between week 1 and week 6 will be calculated.
Measured: Up to 6 weeks, or until wound healing, withdrawal, or discontinuation, whichever occurs first.
Change in Weekly Average Sit-to-Stand Transitions
The sit-to-stand transitions will be assessed using a wrist-worn accelerometer applied at baseline and worn throughout the study period. Sit-to-stand transitions is defined as posture changes from sitting or lying to standing occurring within a 24-hour period. Daily counts will be aggregated to compute weekly average sit-to-stand transitions per participant. Change in sit-to-stand transitions between week 1 and week 6 will be calculated.
Measured: Up to 6 weeks, or until wound healing, withdrawal, or discontinuation, whichever occurs first.
Change in Weekly Average Total Sleep Duration
Sleep outcomes will be assessed using a wrist-worn accelerometer applied at baseline and worn throughout the study period. Total sleep duration is defined as the cumulative duration of all detected sleep events within a 24-hour period and reported in hours.
Daily values will be aggregated to derive weekly average total sleep duration per participant. Change in total sleep duration between week 1 and week 6 will be calculated.
Measured: Up to 6 weeks, or until wound healing, withdrawal, or discontinuation, whichever occurs first.
Change in Weekly Average Sleep Efficiency
Sleep outcomes will be assessed using a wrist-worn accelerometer applied at baseline and worn throughout the study period. Sleep Efficiency is defined as the as the percentage of time spent asleep relative to the total rest interval duration.
Daily sleep efficiency values were aggregated to compute weekly average sleep efficiency per participant. Change in sleep efficiency between week 1 and week 6 will be calculated.
Measured: Up to 6 weeks, or until wound healing, withdrawal, or discontinuation, whichever occurs first.
Change in Weekly Average Sleep Onset Latency
Sleep outcomes will be assessed using a wrist-worn accelerometer applied at baseline and worn throughout the study period. Sleep Onset Latency is defined as the elapsed time between the start of the nightly rest interval and the onset of the first detected sleep episode, expressed in hours.
Daily sleep onset latency values were aggregated to obtain weekly average sleep onset latency per participant. Change in sleep onset latency between week 1 and week 6 will be calculated.
Measured: Up to 6 weeks, or until wound healing, withdrawal, or discontinuation, whichever occurs first.
Social support and satisfaction assessment
Perceived social support and treatment satisfaction will be assessed using the Multidimensional Scale of Perceived Social Support (SSQ). The SSQ is a patient-reported questionnaire that evaluates perceived support from family, friends, and significant others. The instrument consists of 12 items, each rated on a 7-point Likert scale ranging from 1 ("very strongly disagree") to 7 ("very strongly agree"). The global SSQ score is calculated as the mean of all items and ranges from 1 to 7, with higher scores indicating greater perceived social support and lower scores indicating lower perceived support.
Measured: Assessed once during the treatment period of 6 weeks, until healed or withdrawal/discontinuation, whichever occurs first.
For patients with VLU: Compliance with compression therapy
Compliance with compression therapy (for venous leg ulcer patients) will be assessed using patient diaries and visit assessments. Compliance will be categorized as fully compliant (defined as 7 out of 7 days with compression), moderately compliant (defined as 1 to 3 days without compression out of 7 days), or not compliant (defined as >3 days without compression out of 7 days).
Measured: Up to 6 weeks, or until wound healing, withdrawal, or discontinuation, whichever occurs first
For patients with DFU: Compliance to offloading
Compliance with offloading devices (for diabetic foot ulcer patients) will be assessed using patient diaries and visit assessments. Compliance will be categorized as fully compliant (defined as 7 out of 7 days with offloading), moderately compliant (defined as 1 to 3 days without offloading out of 7 days), or not compliant (defined as >3 days without offloading out of 7 days).
Measured: Up to 6 weeks, or until wound healing, withdrawal, or discontinuation, whichever occurs first
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted24 Apr 2026
- Study start17 Jul 2024
- Primary completion21 Aug 2025
- Study completion23 Aug 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Venous Leg Ulcer (VLU)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 80 participants (actual)
Sponsor and investigators
- Lead sponsor
- HARTMANN GROUP
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07549737
- Sponsor's protocol ID
- PHAG-EVO-CH
- Status last verified
- Mar 2026
- First submitted
- 8 Apr 2026
- Last updated
- 24 Apr 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Publications
Probst S, Velickovic V, Mikosinski J, Panczak K, Wegrzynowski A, Piechota D, Kotala M, Lipinski P, Rybolowicz K, Lipinska A, Bil J, Szenk T, Buczak P, Santoso C, Pitchika A, Armstrong DG. Patient-reported outcomes in venous leg ulcers: results from a prospective multicenter single-arm cohort study of silicone superabsorbent polymer dressings. Patient Relat Outcome Meas. 2026 Oct 4;17(1):136-148. doi: 10.1080/1179271X.2026.2734965. eCollection 2026.
PubMed 42847019
Study at a glance
From the registry record, last updated by the sponsor on 24 Apr 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Prospective, Single-arm, Cohort Post Market Clinical Follow Up Investigation to Follow Evolution of the Healing of Exuding Chronic Leg Ulcers Treated With RespoSorb Silicone Border and RespoSorb Silicone Dressings.
- ClinicalTrials.gov ID
- NCT07549737
- Acronym / sponsor ID
- PHAG-EVO-CH
- Conditions
- Venous Leg Ulcer (VLU), Diabetic Foot Ulcer (DFU)
- Keywords
- Venous leg ulcer, Diabetic Foot Ulcer, Silicone superabsorbent dressings
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 80 participants (actual)
- Lead sponsor
- HARTMANN GROUPIndustry (pharma, biotech, devices)
- Study start
- 17 Jul 2024 (actual)
- Primary completion
- 21 Aug 2025 (actual)
- Study completion
- 23 Aug 2025 (actual)
- First posted
- 24 Apr 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this single arm clinical study is to find out how well two Silicone superabsorbent polymer dressings, RespoSorb Silicone (also known as Zetuvit Plus Silicone) and RespoSorb Silicone Border (also known as Zetuvit Plus Silicone Border), work in treating long lasting wounds on the lower legs or feet. The main goal of the study is to see whether these dressings help reduce wound size over time.
The study also looks at whether the dressings improve the condition of the wound and the surrounding skin. In addition, patients are asked about their experience with the dressings, including whether they help reduce pain and how satisfied patients are with the treatment.
Detailed description
This prospective, non comparative, single arm clinical investigation is conducted as part of Post Market Clinical Follow up (PMCF) activities to evaluate the clinical performance and safety of two Silicone SAP dressings: RespoSorb Silicone (RSSil; also marketed as Zetuvit Plus Silicone) and RespoSorb Silicone Border (RSSB; also marketed as Zetuvit Plus Silicone Border) in the management of chronic, exuding lower extremity wounds.
Approximately 80 evaluable adult patients with a single chronic VLU or DFU will be enrolled at 7 to 10 clinical sites in Poland, including outpatient clinics and hospitals. In each dressing group, at least 35% of patients will have VLU and at least 35% DFU. Patients with VLU will receive compression therapy, and patients with DFU will use appropriate offloading devices throughout the study.
Patients will be followed for up to 6 weeks or until wound healing, discontinuation, withdrawal, or occurrence of an adverse event preventing further participation. The primary objective is to evaluate the potential clinical effectiveness of RSSil and RSSB in reducing wound size over time. Wound area will be measured objectively by planimetry using standardized photographs taken at each visit.
Secondary outcomes include changes in wound tissue composition (granulation and slough), exudate amount and type, peri wound skin condition, frequency of dressing changes, and patient reported outcomes such as treatment benefit and wound related quality of life. Physical activity will be assessed using a wrist worn accelerometer, and compliance with compression therapy (VLU) or offloading devices (DFU) will be documented. In addition, healthcare professionals will provide feedback on usability and overall experience with the dressings.
Safety will be assessed by monitoring and recording device related adverse events and device deficiencies throughout the study. Data will be captured using an electronic case report form and analyzed primarily using an intention to treat approach.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Silicone SAP Dressings (RespoSorb Silicone / RespoSorb Silicone Border) | Experimental | Device: RespoSorb Silicone (RSSil), Device: RespoSorb Silicone Border (RSSB)Single-arm cohort of adult patients with chronic, exuding lower extremity wounds treated with Silicone SAP dressings. Participants receive either RespoSorb Silicone or RespoSorb Silicone Border, selected based on wound characteristics and clinical judgement, and are followed prospectively to assess wound area reduction, wound-bed condition, patient-reported outcomes, and safety. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (13 listed)
- Patient is 18 years of age or older and has given formal written consent.
- Diagnosed with a chronic, exuding lower extremity wound of a single limb:
- Target ulcer persists since min. 1 and max. 12 months prior to screening.
- An appropriate dressing size is available to be used according to the size of the target ulcer, the ulcer size shall be no longer than 10 cm in one dimension.
- Target ulcer is not clinically infected ( Clinically infected wound is defined as a wound that required the use of systemic antibiotics or topical antimicrobials ).
Key exclusion criteria (28 listed)
- Known allergies/hypersensitivity or intolerance to any of the study product ingredients.
- Patients with ischemic diabetic foot ulcers.
- Patients with more than two full-thickness lower extremity ulcers on the same limb or greater than a total of three full-thickness lower-extremity ulcers.
- Target ulcer is clinically infected according to the judgement of HCP or suspected to be clinically infected that could require systemic antibiotics at the time of screening or during the study.
- Treatment with local or systemic antimicrobial therapy within 7 days prior to Screening visit or during the study duration.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| RespoSorb Silicone (RSSil)Also: Zetuvit Plus SiliconeRespoSorb Silicone is a Silicone Superabsorbent Polymer (SAP) dressing intended for the management of chronic, exuding lower extremity wounds. The dressing consists of a superabsorbent core designed to absorb and retain wound exudate and a soft silicone contact layer that allows gentle adhesion to the peri-wound skin while minimizing trauma and pain during dressing changes. RespoSorb Silicone is applied directly to the wound bed and secured with an appropriate secondary fixation according to standard clinical practice and the manufacturer's Instructions for Use. Dressing changes are performed as clinically indicated. Treatment is continued for up to 6 weeks or until wound healing, discontinuation, or withdrawal. | Device | Silicone SAP Dressings (RespoSorb Silicone / RespoSorb Silicone Border) |
| RespoSorb Silicone Border (RSSB)Also: Zetuvit Plus Silicone BorderRespoSorb Silicone Border is a Silicone Superabsorbent Polymer (SAP) dressing intended for the management of chronic, exuding lower extremity wounds. The dressing combines a superabsorbent core for effective exudate absorption and retention with a soft silicone contact layer to minimize disruption of the wound and peri-wound skin. The dressing includes an integrated adhesive silicone border that provides secure fixation without the need for additional secondary dressings. RespoSorb Silicone Border is applied according to standard clinical practice and the manufacturer's Instructions for Use. Dressing changes are performed as clinically indicated. Treatment is continued for up to 6 weeks or until wound healing, discontinuation, or withdrawal. | Device | Silicone SAP Dressings (RespoSorb Silicone / RespoSorb Silicone Border) |
Primary outcome
Wound area reduction
Time frame: Up to 6 weeks (maximum total treatment period), or until wound healing, withdrawal, or discontinuation, whichever occurs first
Clinical effectiveness will be assessed by the change in wound area of the target ulcer over time. Wound area will be calculated in square centimeters (cm²) using planimetric analysis based on standardized digital photographs taken at each study visit. The study has established a threshold for clinical significance, defining a minimum reduction in the wound area of 20%.
18 secondary outcomes
Change in granulation tissue over time
Time frame: Up to 6 weeks, or until wound healing, withdrawal, or discontinuation, whichever occurs first
Change in Slough Tissue Over Time
Time frame: Up to 6 weeks, or until wound healing, withdrawal, or discontinuation, whichever occurs first
Change in Exudate Amount Over Time
Time frame: Weekly assessments during the treatment period, up to 6 weeks, or until wound healing, withdrawal, or discontinuation, whichever occurs first.
Change in Exudate Type Over Time
Time frame: Up to 6 weeks, or until wound healing, withdrawal, or discontinuation, whichever occurs first
Improvement of Peri-Wound Skin Condition Over Time
Time frame: Up to 6 weeks, or until wound healing, withdrawal, or discontinuation, whichever occurs first.
Patient-Reported Treatment Benefit (PBI-W)
Time frame: Assessed at baseline and at the end of treatment at 6 weeks or until healed or withdrawal/discontinuation, whichever occurs first.
Quality of Life of patients with chronic wounds
Time frame: Assessed at baseline and at the end of treatment at 6 weeks or until healed or withdrawal/discontinuation, whichever occurs first.
Change in weekly Average Active Intensity
Time frame: Up to 6 weeks, or until wound healing, withdrawal, or discontinuation, whichever occurs first.
Change in Weekly Average Active Volume
Time frame: Up to 6 weeks, or until wound healing, withdrawal, or discontinuation, whichever occurs first.
Change in Weekly Average Moderate-to-Vigorous Physical Activity (MVPA) Duration
Time frame: Up to 6 weeks, or until wound healing, withdrawal, or discontinuation, whichever occurs first.
Change in Weekly Average Active-to-Inactive Duration Ratio
Time frame: Up to 6 weeks, or until wound healing, withdrawal, or discontinuation, whichever occurs first.
Change in Weekly Average Sit-to-Stand Transitions
Time frame: Up to 6 weeks, or until wound healing, withdrawal, or discontinuation, whichever occurs first.
Change in Weekly Average Total Sleep Duration
Time frame: Up to 6 weeks, or until wound healing, withdrawal, or discontinuation, whichever occurs first.
Change in Weekly Average Sleep Efficiency
Time frame: Up to 6 weeks, or until wound healing, withdrawal, or discontinuation, whichever occurs first.
Change in Weekly Average Sleep Onset Latency
Time frame: Up to 6 weeks, or until wound healing, withdrawal, or discontinuation, whichever occurs first.
Social support and satisfaction assessment
Time frame: Assessed once during the treatment period of 6 weeks, until healed or withdrawal/discontinuation, whichever occurs first.
For patients with VLU: Compliance with compression therapy
Time frame: Up to 6 weeks, or until wound healing, withdrawal, or discontinuation, whichever occurs first
For patients with DFU: Compliance to offloading
Time frame: Up to 6 weeks, or until wound healing, withdrawal, or discontinuation, whichever occurs first
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 24 Apr 2026.
- Derived from this study: PubMed 42847019Probst S, Velickovic V, Mikosinski J, Panczak K, Wegrzynowski A, Piechota D, Kotala M, Lipinski P, Rybolowicz K, Lipinska A, Bil J, Szenk T, Buczak P, Santoso C, Pitchika A, Armstrong DG. Patient-reported outcomes in venous leg ulcers: results from a prospective multicenter single-arm cohort study of silicone superabsorbent polymer dressings. Patient Relat Outcome Meas. 2026 Oct 4;17(1):136-148. doi: 10.1080/1179271X.2026.2734965. eCollection 2026.
- Individual participant dataSharing planned: Undecided
Related trials for Venous Leg Ulcer (VLU)
Not yet recruitingPhase 2
Controlled Study, Performed to Evaluate the Safety and Efficacy of EscharEx and Its Placebo (Gel Vehicle) Compared to Non-surgical Standard of Care in Participants With Venous Leg Ulcers (VLU)
Venus Leg Ulcers
RecruitingPhase 3
A Double Blind Study Performed to Evaluate the Efficacy and the Safety of EscharEx in Debridement of VLU (VALUE)
Venous Leg Ulcer (VLU)
Not yet recruitingPhase 1/2
Evaluating Autologous Platelet-Rich Fibrin Plasma for Chronic Lower Extremity Ulcers
Lower Extremity, Chronic Ulcers
Recruiting
Efficacy of Human Placental Membrane Products and Standard of Care in the Management of Nonhealing Diabetic Foot Ulcers and Venous Leg Ulcers
Diabetic Foot Ulcer, Foot Ulcer Chronic
Recruiting
Effect of Photobiomodulation on Healing of Venous Leg Ulcers
Venous Leg Ulcer (VLU), Venous Hypertension Ulcers
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
8 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing RespoSorb Silicone (RSSil) and RespoSorb Silicone Border (RSSB) in people with Venous Leg Ulcer (VLU) and Diabetic Foot Ulcer (DFU), run by HARTMANN GROUP at 8 sites in Poland.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 13 inclusion and 28 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 24 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 8 sites in Poland. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Wound area reduction (time frame: Up to 6 weeks (maximum total treatment period), or until wound healing, withdrawal, or discontinuation, whichever occurs first). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07549737, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Apr 2026.